Oncolytic Viruses and Its Commercialization A mini review

키워드

참고문헌 (78)

1. Langenberg MH, "Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors", Ann Oncol, 22, pp.2508~2515 (2011)
2. Tan KX, "Towards targeted cancer therapy: Aptamer or oncolytic virus?", Eur J Pharm Sci, 96, pp.8~19 (2016)
3. Lolkema MP, "A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer", Clin Cancer Res, 17, pp.581~588 (2011)
4. Singh PK, "Oncolytic viruses & their specific targeting to tumour cells", Indian J Med Res, 136, pp.571~584 (2012)
5. Kaufman HL, "Oncolytic viruses : a new class of immunotherapy drugs", Nat Rev Drug Discov, 14, pp.642~662 (2015)
6. Fukuhara H, "Oncolytic virus therapy : A new era of cancer treatment at dawn", Cancer Sci, 107, pp.1373~1379 (2016)
7. Pack GT, "Note on the experimental use of rabies vaccine for melanomatosis", AMA archives of dermatology and syphilology, 62, pp.694~695 (1950)
8. Kelly E, "History of oncolytic viruses : genesis to genetic engineering", Mol Ther, 15, pp.651~659 (2007)
9. Huebner RJ, "Studies of adenoidal-pharyngeal-conjunctival vaccines in volunteers", J Am Med Assoc, 159, pp.986~989 (1955)
10. Rowe WP, "Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture", Proc Soc Exp Biol Med, 84, pp.570~573 (1953)
11. Huebner RJ, "Studies on the use of viruses in the treatment of carcinoma of the cervix", Cancer, 9, pp.1211~1218 (1956)
12. Georgiades J, "Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report", Biul Inst Med Morsk Gdansk, 10, pp.49~57 (1959)
13. Zielinski T, "Remote results of clinical observation of the oncolytic action of adenoviruses on cervix cancer", Nowotwory, 19, pp.217~221 (1969)
14. Southam CM, "Induced virus infections in man by the Egypt isolates of West Nile virus", Am J Trop Med Hyg, 3, pp.19~50 (1954)
15. Ring CJ, "Cytolytic viruses as potential anti-cancer agents", J Gen Virol, 83, pp.491~502 (2002)
16. Kreppel F, "Modification of adenovirus gene transfer vectors with synthetic polymers : a scientific review and technical guide", Mol Ther, 16, pp.16~29 (2008)
17. Lawler SE, "Oncolytic Viruses in Cancer Treatment : A Review", JAMA Oncol (2016)
18. Di Piazza M, "Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells", J Virol, 81, pp.4186~4198 (2007)
19. Guse K, "Oncolytic vaccinia virus for the treatment of cancer", Expert Opin Biol Ther, 11, pp.595~608 (2011)
20. Kim JH, "Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF", Mol Ther, 14, pp.361~370 (2006)
21. Dmitriev I, "An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism", J Virol, 72, pp.9706~9713 (1998)
22. Lu YC, "Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma", Oncol Rep, 28, pp.21~26 (2012)
23. Merrill MK, "Poliovirus receptor CD155-targeted oncolysis of glioma", Neuro Oncol, 6, pp.208~217 (2004)
24. Mader EK, "Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model", Clin Cancer Res, 15, pp.7246~7255 (2009)
25. Tesfay MZ, "PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice", J Virol, 87, pp.3752~3759 (2013)
26. Elankumaran S, "Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy", J Virol, 84, pp.3835~3844 (2010)
27. Ghebremedhin B, "Human adenovirus : Viral pathogen with increasing importance", Eur J Microbiol Immunol(Bp), 4, pp.26~33 (2014)
28. Williams PD, "Development of viral vectors for use in cardiovascular gene therapy", Viruses, 2, pp.334~371 (2010)
29. Trotman LC, "Import of adenovirus DNA involves the nuclear pore complex receptor CAN", Nup214 and histone H1, 2001, pp.3, 1092~1100
30. Alemany R, "Designing adenoviral vectors for tumor-specific targeting", Methods Mol Biol, 542, pp.57~74 (2009)
31. Dynlacht BD, "E2F and p53 make a nice couple : converging pathways in apoptosis", Cell Death and Differentiation, 12, pp.313~314 (2005)
32. Berk AJ, "Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus", Oncogene, 24, pp.7673~7685 (2005)
33. Rao L, "The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins", Proc Natl Acad Sci U S A, 89, pp.7742~7746 (1992)
34. Harada JN, "p53-Independent and-dependent requirements for E1B-55K in adenovirus type 5 replication", J Virol, 73, pp.5333~5344 (1999)
35. McCormick F, "ONYX-015 selectivity and the p14ARF pathway", Oncogene, 19, pp.6670~6672 (2000)
36. Au T, "Minimal hepatic toxicity of Onyx-015 : spatial restriction of coxsackie-adenoviral receptor in normal liver", Cancer Gene Ther, 14, pp.139~150 (2007)
37. Khuri FR, "a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer", Nat Med, 6, pp.879~885 (2000)
38. Crompton AM, "From ONYX-015 to armed vaccinia viruses : the education and evolution of oncolytic virus development", Curr Cancer Drug Targets, 7, pp.133~139 (2007)
39. Kimball KJ, "A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases", Clin Cancer Res, 16, pp.5277~5287 (2010)
40. Jiang H, "Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model", PLoS One, 9, pp.e97407~ (2014)
41. Kuhn I, "Directed evolution generates a novel oncolytic virus for the treatment of colon cancer", PLoS One, 3, pp.e2409~ (2008)
42. Kaufman HL, "Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma", Ann Surg Oncol, 17, pp.718~730 (2010)
43. Roth JC, "Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates", Hum Gene Ther Clin Dev (2014)
44. Liu BL, "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties", Gene Ther, 10, pp.292~303 (2003)
45. Andtbacka RH, "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma", J Clin Oncol, 33, pp.2780~2788 (2015)
46. Strong JE, "The molecular basis of viral oncolysis : usurpation of the Ras signaling pathway by reovirus", EMBO J, 17, pp.3351~3362 (1998)
47. Lawson KA, "Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma", Clin Cancer Res (2016)
48. Danthi P, "From touchdown to transcription : the reovirus cell entry pathway", Curr Top Microbiol Immunol, 343, pp.91~119 (2010)
49. Errington F, "Reovirus activates human dendritic cells to promote innate antitumor immunity", J Immunol, 180, pp.6018~6026 (2008)
50. Harrington KJ, "Clinical trials with oncolytic reovirus : moving beyond phase I into combinations with standard therapeutics", Cytokine Growth Factor Rev, 21, pp.91~98 (2010)
51. Karapanagiotou EM, "Phase I", II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies, 2012, pp.18, 2080~2089
52. Thirukkumaran CM, "Oncolytic viral therapy for prostate cancer : efficacy of reovirus as a biological therapeutic", Cancer Res, 70, pp.2435~2444 (2010)
53. Gollamudi R, "Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors", Invest New Drugs, 28, pp.641~649 (2010)
54. Harrow S, "HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma : safety data and long-term survival", Gene Ther, 11, pp.1648~1658 (2004)
55. Herman JR, "In situ gene therapy for adenocarcinoma of the prostate : a phase I clinical trial", Hum Gene Ther, 10, pp.1239~1249 (1999)
56. Yu P, "Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors", J Exp Med, 201, pp.779~791 (2005)
57. Yoshihara C, "Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings : therapeutic effect on metastatic ovarian cancer", Oncol Rep, 23, pp.733~738 (2010)
58. Liu WH, "Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats", J Cancer Res Clin Oncol, 141, pp.1767~1778 (2015)
59. Guo H, "The regulation of Tolllike receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells", Mol Cancer, 12, pp.77~ (2013)
60. Chen X, "Clinical value of integrated-signature miRNAs in colorectal cancer : miRNA expression profiling analysis and experimental validation", Oncotarget, 6, pp.37544~37556 (2015)
61. Worthley DL, "Colorectal cancer : molecular features and clinical opportunities", Clin Biochem Rev, 31, pp.31~38 (2010)
62. Ginn SL, "Gene therapy clinical trials worldwide to 2012-an update", J Gene Med, 15, pp.65~77 (2013)
63. Luo Q, "A novel E1B55k-Da-deleted oncolytic adenovirus carrying microRNA-143 exerts specific antitumor efficacy on colorectal cancer cells", Am J Transl Res, 8, pp.3822~3830 (2016)
64. Ylosmaki E, "Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA", J Virol, 82, pp.11009~11015 (2008)
65. Russell SJ, "Oncolytic virotherapy", Nat Biotechnol, 30, pp.658~670 (2012)
66. Jung BK, "Mild Hyperthermia Induced by Gold Nanorod-Mediated Plasmonic Photothermal Therapy Enhances Transduction and Replication of Oncolytic Adenoviral Gene Delivery", ACS Nano (2016)
67. Larson C, "Going viral : a review of replication-selective oncolytic adenoviruses", Oncotarget, 6, pp.19976~19989 (2015)
68. Rehman H, "Into the clinic : Talimogene laherparepvec(T-VEC), a first-inclass intratumoral oncolytic viral therapy", J Immunother Cancer, 4, pp.53~ (2016)
69. Yu Z, "Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma", Clin Cancer Res, 11, pp.4889~4897 (2005)
70. Mansour M, "Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells", J Virol, 85, pp.6015~6023 (2011)
71. Bar S, "Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning", PLoS Pathog, 4, pp.e1000126~ (2008)
72. Sova P, "A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases", Mol Ther, 9, pp.496~509 (2004)
73. Fulci G, "Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses", Proc Natl Acad Sci U S A, 103, pp.12873~12878 (2006)
74. Yi L, "CRISPR-Cas9 therapeutics in cancer : promising strategies and present challenges", Biochim Biophys Acta, 1866, pp.197~207 (2016)
75. Yuan M, "CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses", Viruses, 8, pp.72~ (2016)
76. Swift SL, "Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy", Viruses, 8 (2016)
77. Zamarin D, "Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy", Sci Transl Med, 6, pp.226ra232~ (2014)
78. Park YJ, "Regenerative Applications Using Tooth Derived Stem Cells in Other Than Tooth Regeneration : A Literature Review", Stem Cells Int, 2016, pp.9305986~ (2016)

관련 논문AI추천